Alessandra Ravaioli

List of Publications by Year
in descending order

58	2,258	567281 15	214800 47
papers	citations	h-index	g-index

61	61	61	4620
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Effects of Attendance to an Organized Fecal Immunochemical Test Screening Program on the Risk of Colorectal Cancer: An Observational Cohort Study. Clinical Gastroenterology and Hepatology, 2022, 20, 2373-2382.	4.4	14
2	The relative contribution of the decreasing trend in tumourÂthickness to the 2010s increase in net survival fromÂcutaneous malignant melanoma in Italy: a populationâ€based investigation*. British Journal of Dermatology, 2022, 187, 52-63.	1.5	11
3	How a faecal immunochemical test screening programme changes annual colorectal cancer incidence rates: an Italian intention-to-screen study. British Journal of Cancer, 2022, 127, 541-548.	6.4	12
4	Clinical Epidemiology of Microinvasive Cervical Carcinoma in an Italian Population Targeted by a Screening Programme. Cancers, 2022, 14, 2093.	3.7	1
5	Midâ€term trends and recent birthâ€cohortâ€dependent changes in incidence rates of cutaneous malignant melanoma in Italy. International Journal of Cancer, 2021, 148, 835-844.	5.1	13
6	Incidence of interval breast cancer among women aged 45â€“49 in an organised mammography screening setting. Journal of Medical Screening, 2021, 28, 207-209.	2.3	4
7	Five-year annual incidence and clinico-molecular features of breast cancer after the last negative screening mammography at age 68â€“69. European Radiology, 2021, , 1.	4.5	0
8	Changes in the incidence of cervical tumours by disease stage in a cytology-based screening programme. Journal of Medical Screening, 2020, 27, 96-104.	2.3	1
9	Detection by screening introduces biases into survival estimates for luminal Aâ€like breast cancer patients. International Journal of Cancer, 2020, 146, 1764-1766.	5.1	2
10	Time trends and ageâ€“periodâ€“cohort analysis of cutaneous malignant melanoma incidence rates in the Romagna Region (northern Italy), 1986â€“2014. Melanoma Research, 2020, 30, 198-205.	1.2	6
11	Proportional incidence of interval colorectal cancer in a large population-based faecal immunochemical test screening programme. Digestive and Liver Disease, 2020, 52, 452-456.	0.9	10
12	Incidence trends of vulvar squamous cell carcinoma in Italy from 1990 to 2015. Gynecologic Oncology, 2020, 157, 656-663.	1.4	19
13	Estimating the impact of an organised screening programme on cervical cancer incidence: A 26â€year study from northern Italy. International Journal of Cancer, 2019, 144, 1017-1026.	5.1	20
14	Annual mammography at age 45â€“49Âyears and biennial mammography at age 50â€“69Âyears: comparing performance measures in an organised screening setting. European Radiology, 2019, 29, 5517-5527.	4.5	9
15	Evaluation of the agreement between TNM 7th and 8th in a populationâ€based series of cutaneous melanoma. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 521-524.	2.4	7
16	Early Gastric Cancer: Clinical Behavior and Treatment Options. Results of an Italian Multicenter Study on Behalf of the Italian Gastric Cancer Research Group (GIRCG). Oncologist, 2018, 23, 852-858.	3.7	10
17	The impact of overdiagnosis on thyroid cancer epidemic in Italy,1998â€“2012. European Journal of Cancer, 2018, 94, 6-15.	2.8	58
18	Strategies for delivery of faecal occult blood test kits and participation to colorectal cancer screening in the Emilia-Romagna Region of Italy. European Journal of Cancer Care, 2018, 27, e12631.	1.5	4

#	Article	IF	Citations
19	A model of an inflammatory bowel disease population-based registry: The ForlÃ¬ experience (1993â€“2013). Digestive and Liver Disease, 2018, 50, 32-36.	0.9	14
20	Hormone receptor-positive invasive lobular and ductal carcinoma of the breast have comparable hormone receptor expression levels both if detected by screening and clinically. Breast Cancer Research and Treatment, 2018, 167, 817-818.	2.5	1
21	The Results of an Italian Quality Assurance Program Support the New American Society for Colposcopy and Cervical Pathology Recommendations for Colposcopy Practice. Journal of Lower Genital Tract Disease, 2018, 22, 235-236.	1.9	1
22	Reducing harms from treatment. Sixteen years of surgery of the axilla for screen-detected breast cancers in Italy. Breast, 2018, 42, 15-22.	2.2	1
23	Advanced breast cancer rates in the epoch of service screening: The 400,000 women cohort study from Italy. European Journal of Cancer, 2017, 75, 109-116.	2.8	50
24	Early (short-interval) rescreen in mammography screening. Journal of Medical Screening, 2017, 24, 54-55.	2.3	0
25	Incidence and survival trends of cervical adenocarcinoma in Italy: Cytology screening has become more effective in downstaging the disease but not in detecting its precursors. International Journal of Cancer, 2017, 140, 247-248.	5.1	4
26	Socioeconomic deprivation worsens the outcomes of Italian women with hormone receptor-positive breast cancer and decreases the possibility of receiving standard care. Oncotarget, 2017, 8, 68402-68414.	1.8	8
27	Immigrants and cancer in Italy: a literature review. Annali Dell'Istituto Superiore Di Sanita, 2017, 53, 238-245.	0.4	0
28	Patterns and determinants of receipt of follow-up mammography and/or clinical examination in a cohort of Italian breast cancer survivors. Breast Cancer Research and Treatment, 2016, 158, 543-551.	2.5	16
29	The Relationship Between Gastric and Esophageal Cancers in Italy. American Journal of Gastroenterology, 2016, 111, 1201-1202.	0.4	2
30	Interpretation of colposcopy in population-based cervical screening services in north-eastern Italy: an online interregional agreement study. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2016, 206, 64-69.	1.1	4
31	Coping with problems that flaw the estimate of mammography sensitivity in population-based screening programmes: the Italian perspective. Public Health, 2016, 136, 178-180.	2.9	3
32	An Integrated High-Density Power Management Solution for Portable Applications Based on a Multioutput Switched-Capacitor Circuit. IEEE Transactions on Power Electronics, 2016, 31, 4305-4323.	7.9	38
33	Gastric cancer incidence in the Romagna Region of Italy: A spatial and temporal analysis. Digestive and Liver Disease, 2015, 47, 1076-1081.	0.9	8
34	Audit system on Quality of breast cancer diagnosis and Treatment (QT): results of quality indicators on screen-detected lesions in Italy, 2011-2012. Epidemiologia E Prevenzione, 2015, 39, 40-7.	1.1	7
35	Problems, solutions, and perspectives in the evaluation of interval cancers in Italian mammography screening programmes: a position paper from the Italian group for mammography screening (GISMa). Epidemiologia E Prevenzione, 2015, 39, 52-7.	1.1	1
36	Cancer survival in Europe 1999â€“2007 by country and age: results of EUROCARE-5â€”a population-based study. Lancet Oncology, The, 2014, 15, 23-34.	10.7	1,554

#	Article	IF	Citations
37	Cancer prevalence estimates in Europe at the beginning of 2000. Annals of Oncology, 2013, 24, 1660-1666.	1.2	36
38	Survival and cure trends for European children, adolescents and young adults diagnosed with acute lymphoblastic leukemia from 1982 to 2002. Haematologica, 2013, 98, 744-752.	3.5	35
39	Estimates of cancer burden in Emilia-Romagna. Tumori, 2013, 99, 327-333.	1.1	0
40	Estimates of cancer burden in Emilia-Romagna. Tumori, 2013, 99, 327-33.	1.1	0
41	Ageing and other factors behind recent cancer incidence and mortality trends in Italy. Journal of Geriatric Oncology, 2012, 3, 111-119.	1.0	5
42	Incidence, detection, and tumour stage of breast cancer in a cohort of Italian women with negative screening mammography report recommending early (short-interval) rescreen. BMC Medicine, 2010, 8, 11.	5.5	9
43	Receipt of adjuvant systemic therapy among patients with high-risk breast cancer detected by mammography screening. Breast Cancer Research and Treatment, 2009, 113, 559-566.	2.5	6
44	Effectiveness of service screening: a caseâ€“control study to assess breast cancer mortality reduction. British Journal of Cancer, 2008, 99, 423-427.	6.4	75
45	Breast screening: Axillary lymph node status of interval cancers by interval year. Breast, 2008, 17, 477-483.	2.2	5
46	Evaluation of service mammography screening impact in Italy. The contribution of hazard analysis. European Journal of Cancer, 2008, 44, 858-865.	2.8	10
47	Incidence of interval breast cancers after 650,000 negative mammographics in 13 Italian health districts. Journal of Medical Screening, 2008, 15, 30-35.	2.3	34
48	Risk of Cancer of the Prostate and of the Kidney Parenchyma following Bladder Cancer. Tumori, 2007, 93, 124-128.	1.1	4
49	Basal level and behaviour of cytokines in a randomized outpatient trial comparing chemotherapy and biochemotherapy in metastatic melanoma. Melanoma Research, 2006, 16, 317-323.	1.2	10
50	Relative and absolute cancer mortality of women in agriculture in northern Italy. European Journal of Cancer Prevention, 2005, 14, 337-344.	1.3	9
51	Screen-detected vs clinical breast cancer: the advantage in the relative risk of lymph node metastases decreases with increasing tumour size. British Journal of Cancer, 2005, 92, 156-161.	6.4	21
52	An inverse association between tumour size and overdiagnosis may explain the results by Bucchi et al. British Journal of Cancer, 2005, 92, 1814-1814.	6.4	0
53	Reply: An inverse association between tumour size and overdiagnosis may explain the results by Bucchi et al. British Journal of Cancer, 2005, 92, 1815-1816.	6.4	0
54	Cancer Mortality in a Cohort of Male Agricultural Workers From Northern Italy. Journal of Occupational and Environmental Medicine, 2004, 46, 249-256.	1.7	22

#	Article	IF	Citations
55	Temozolomide and interferon-alpha in metastatic melanoma: a phase II study of the Italian Melanoma Intergroup. Melanoma Research, 2004, 14, 295-299.	1.2	16
56	Fibrinogen: a novel predictor of responsiveness in metastatic melanoma patients treated with bio-chemotherapy: IMI (italian melanoma inter-group) trial. Journal of Translational Medicine, 2003, 1, 13.	4.4	10
57	Chemotherapy and Bio-Chemotherapy in Patients with Advanced Melanoma: Combination Therapy with a Nitrosourea. Journal of Chemotherapy, 2003, 15, 198-202.	1.5	3
58	Adjuvant Immunotherapy With Tumor Infiltrating Lymphocytes and Interleukin-2 in Patients With Resected Stage III and IV Melanoma. Journal of Immunotherapy, 2003, 26, 156-162.	2.4	22